{"id":"https://openalex.org/W7170111113","doi":null,"title":"Beyond the Usual Targets: A Case Report of Overcoming IL-23 and IL-17A Biologic Nonresponse in Palmoplantar Psoriasis With Brodalumab.","display_name":"Beyond the Usual Targets: A Case Report of Overcoming IL-23 and IL-17A Biologic Nonresponse in Palmoplantar Psoriasis With Brodalumab.","publication_year":2026,"publication_date":"2026-07-22","ids":{"openalex":"https://openalex.org/W7170111113","pmid":"https://pubmed.ncbi.nlm.nih.gov/42482974"},"language":"en","primary_location":{"id":"pmid:42482974","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42482974","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical and aesthetic dermatology","raw_type":"Case Reports"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pubmed.ncbi.nlm.nih.gov/42482974/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106386728","display_name":"Kyle T. Machynia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I134113660","display_name":"University of Nevada, Reno","ror":"https://ror.org/01keh0577","country_code":"US","type":"education","lineage":["https://openalex.org/I134113660"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kyle Machynia","raw_affiliation_strings":["Mr. Machynia is with University of Nevada, Reno School of Medicine, Reno, Nevada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mr. Machynia is with University of Nevada, Reno School of Medicine, Reno, Nevada","institution_ids":["https://openalex.org/I134113660"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5106386728"],"corresponding_institution_ids":["https://openalex.org/I134113660"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.51064415,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"5-6 Suppl 1","first_page":"S10","last_page":"S14"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/palmoplantar-psoriasis","display_name":"palmoplantar psoriasis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/brodalumab","display_name":"brodalumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.7630000114440918},{"id":"https://openalex.org/keywords/il-23","display_name":"IL-23","score":0.9369999766349792},{"id":"https://openalex.org/keywords/treatment-resistant-psoriasis","display_name":"treatment-resistant psoriasis","score":0.7609999775886536},{"id":"https://openalex.org/keywords/guselkumab","display_name":"guselkumab","score":0.9350000023841858},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.621999979019165},{"id":"https://openalex.org/keywords/occupational-impairment","display_name":"occupational impairment","score":0.3269999921321869}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9200000166893005},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.8461999893188477},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.7644000053405762},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.515999972820282},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4108999967575073},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.336899995803833},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.3303999900817871},{"id":"https://openalex.org/C2778616394","wikidata":"https://www.wikidata.org/wiki/Q474959","display_name":"myalgia","level":2,"score":0.29440000653266907},{"id":"https://openalex.org/C2909516574","wikidata":"https://www.wikidata.org/wiki/Q2562329","display_name":"Palmoplantar pustulosis","level":3,"score":0.28679999709129333},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.28439998626708984},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.28130000829696655},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.26109999418258667},{"id":"https://openalex.org/C2778384578","wikidata":"https://www.wikidata.org/wiki/Q16930687","display_name":"Therapeutic approach","level":3,"score":0.2549000084400177},{"id":"https://openalex.org/C2778674544","wikidata":"https://www.wikidata.org/wiki/Q1414805","display_name":"Systemic disease","level":3,"score":0.250900000333786},{"id":"https://openalex.org/C156730664","wikidata":"https://www.wikidata.org/wiki/Q23308590","display_name":"Interleukin 23","level":4,"score":0.25060001015663147}],"mesh":[],"locations_count":2,"locations":[{"id":"pmid:42482974","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42482974","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical and aesthetic dermatology","raw_type":"Case Reports"},{"id":"pmh:oai:pubmedcentral.nih.gov:13387641","doi":null,"is_oa":true,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42482974/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"J Clin Aesthet Dermatol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:13387641","doi":null,"is_oa":true,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42482974/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"J Clin Aesthet Dermatol","raw_type":"Text"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.6876178979873657,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"INTRODUCTION:":[0],"Palmoplantar":[1],"psoriasis":[2,9,119,139,189],"is":[3,109],"a":[4,110,114],"clinically":[5],"challenging":[6],"variant":[7],"of":[8,31,183],"in":[10,45,65,75,99,159,186],"which":[11,93],"lesions":[12],"confined":[13],"to":[14,25,123],"the":[15,152,171,180],"palms":[16],"and":[17,22,41,54,61,125,140,146,170,190],"soles":[18],"frequently":[19],"impair":[20],"function":[21],"prove":[23],"refractory":[24],"conventional":[26],"therapeutic":[27],"approaches.":[28],"A":[29,82,128],"range":[30],"therapies,":[32],"including":[33],"topical":[34,124],"corticosteroids,":[35],"phototherapy,":[36],"systemic":[37,126],"agents,":[38],"small":[39],"molecules,":[40],"biologics,":[42,49],"are":[43,56,62,70],"used":[44],"palmoplantar":[46,66,118,138,198],"psoriasis.":[47,77],"Among":[48],"those":[50],"targeting":[51],"interleukin":[52],"(IL)-17":[53],"IL-23":[55],"guideline-endorsed":[57],"for":[58,96,197],"moderate-to-severe":[59],"disease":[60],"commonly":[63],"employed":[64],"involvement,":[67],"although":[68],"responses":[69],"often":[71],"less":[72],"predictable":[73],"than":[74],"plaque":[76],"Brodalumab,":[78],"an":[79],"IL-17":[80,90],"receptor":[81],"(IL-17RA)":[83],"antagonist,":[84],"uniquely":[85],"inhibits":[86],"signaling":[87],"from":[88],"multiple":[89],"family":[91],"cytokines,":[92],"could":[94],"account":[95],"its":[97,195],"efficacy":[98],"patients":[100],"who":[101],"fail":[102],"other":[103],"targeted":[104],"therapies.":[105],"CASE":[106],"REPORT:":[107],"This":[108,177],"case":[111,178],"report":[112],"on":[113],"patient":[115,132,172],"presenting":[116],"with":[117,133,136,144,166],"that":[120],"was":[121,141],"resistant":[122],"corticosteroids.":[127],"62-year-old":[129],"White":[130],"male":[131],"obesity":[134],"presented":[135],"chronic":[137],"unsuccessfully":[142],"treated":[143],"guselkumab":[145],"ixekizumab.":[147],"Disease":[148],"persistence":[149],"severely":[150],"affected":[151],"patient's":[153],"work":[154],"performance.":[155],"Brodalumab":[156],"initiation":[157],"resulted":[158],"complete":[160],"skin":[161],"clearance":[162],"within":[163],"3":[164],"months":[165],"no":[167],"adverse":[168],"effects,":[169],"resumed":[173],"working":[174],"full-time.":[175],"CONCLUSION:":[176],"highlights":[179],"potential":[181],"role":[182],"IL-17RA":[184],"blockade":[185],"localized,":[187],"treatment-resistant":[188],"supports":[191],"further":[192],"investigation":[193],"into":[194],"use":[196],"disease.":[199]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2026-07-23T00:00:00"}